![THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018) THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018)](https://eje.bioscientifica.com/view/journals/eje/179/1/images/EJE-18-0056fig1.jpeg)
THERAPY OF ENDOCRINE DISEASE: Denosumab vs bisphosphonates for the treatment of postmenopausal osteoporosis in: European Journal of Endocrinology Volume 179 Issue 1 (2018)
![Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials - Clinical Therapeutics Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/e2da7a61-c58d-47e0-b52f-d2ce3363c9d7/gr1_lrg.jpg)
Denosumab Versus Zoledronic Acid in the Prevention of Skeletal-related Events in Vulnerable Cancer Patients: A Meta-analysis of Randomized, Controlled Trials - Clinical Therapeutics
![Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library Denosumab: mechanism of action and clinical outcomes - Hanley - 2012 - International Journal of Clinical Practice - Wiley Online Library](https://onlinelibrary.wiley.com/cms/asset/7398e176-88ff-477a-9180-418cab6dba3d/ijcp_12022_f1.gif)